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A B S T R A C T
Purpose: The goals of this study are to evaluate the efﬁcacy and tolerability of levetiracetam (LEV) as add-
on therapy in children with refractory epilepsies and to determine the value of LEV blood level
monitoring in this population.
Methods: Sixty-nine children (39 males and 30 females) treated with LEV between 2006 and 2007 were
selected. Their medical ﬁles were reviewed for LEV efﬁcacy and tolerability. In a subgroup of children
currently taking LEV, plasma concentrations were determined by high performance liquid chromato-
graphy by ultraviolet detection (HPLC-UV) method and correlated with the given dose per kilo as well as
clinical response.
Results: Fifty-one patients (74%) had a more than 50% reduction in seizure frequency with 16 patients
(23%) becoming seizure free on LEV. Eighteen (26%) patients had a less than 50% reduction in seizure
frequency. Adverse events due to LEV ranged frommild to moderate in only 18 patients (26%). The most
frequently observed were drowsiness, behavioral difﬁculties, increase in seizure frequency and
headaches. Themajority (60.5%) of the responders received doses between 10 and 50 mg/kg/day and had
a plasma concentration (PC) between 5 and 40 mg/ml. However, we found no clear correlation between
PC and efﬁcacy.
Conclusion: Levetiracetam given twice a day in children with refractory epilepsy reduces seizure
frequency in all types of epilepsy. In children, LEV is a broad spectrum anticonvulsant with a favourable
safety proﬁle.
 2009 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Levetiracetam ([S]-a-ethyl-2-oxo-1-pyrrolidine ace´tamide,
LEV, Keppra1, UCB, Belgium), the latest antiepileptic drugs
(AED) available in Canada (March 2003), is approved as an add-
on therapy to treat refractory partial seizures in children over 4
years old.
It is an enantiopure molecule, the R isomer being inactive. Its
structure, which includes a pyrrolidone, resembles that of
piracetam. LEV demonstrates pharmacokinetic and clinical proﬁle
characteristics desired from an AED: (1) high bio-availability, (2)
rapid achievement of steady-state concentrations, (3) linear and* Corresponding author at: Sainte-Justine Hospital, Neurology Division, Room
5421, 3175 Ste-Catherine Road, Montreal, QC, Canada H3T 1C5.
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E-mail addresses: patricia.giroux@umontreal.ca (P.C. Giroux),
milagros.salas-prato@recherche-ste-justine.qc.ca (M. Salas-Prato),
yves.theoret@umontreal.ca (Y. The´oreˆt), lionel.carmant@umontreal.ca
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1059-1311/$ – see front matter  2009 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2009.05.007time-independent kinetics, (4) limited binding to proteins, (5)
minimal metabolism, and (6) benign dose-dependent side effect
proﬁle.1 The speciﬁc mechanism of action of LEV has not yet been
clearly described, though it has been recognized to be different
from traditional AEDs. Recent studies showed that synaptic
vesicular proteins (SV2A) have a binding site for LEV.2,3 Pisani
et al. demonstrated with electrophysiological recordings that LEV
reduces the amplitude and duration of paroxysmal depolarization
shifts during an epileptiform event, as well as the concomitant
elevation in [Ca2+]i. Also, patch-clamp recordings revealed that LEV
reduces N-, and partially P/Q-type high-voltage-activated Ca2+
currents, but not sodium currents.4 However, other published
studies demonstrate that LEV has no afﬁnity for benzodiazepine-
associated receptors, nor for gamma-aminobutyric acid (GABA)
receptors, re-uptake sites, or second messenger systems.5,6
The use of LEV in the pediatric population with pharmacore-
sistant epilepsy is well documented, yet LEV is not approved in
Canada for generalized seizures.7–14
The goal of the present study is to better deﬁne LEV’s therapeutic
spectrum, adverse event proﬁle, and optimal therapeutic dosagevier Ltd. All rights reserved.
Table 1
Cohort characteristics at time of the study.
Population Total population Drug levels
Number of patients 69 37
Mean age (year) 12  0.5 11.45  0.8
Age range (year) 2.75–20 2.75–18
Male 39 20
Female 30 17
Mental retardation and/or developmental delay 57 30
Number of patients currently on LEV 57 37
LEV PC range (mg/ml) 1.89–74.44
Mean LEV PC (mg/ml) 27.44  3.0
Mean LEV dose (mg/kg/day) 36.30  3.4
Epilepsy type
Generalized 21 15
Partial 48 22
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efﬁcacy in a population of 69 children with epilepsy looking at both
seizure reductionand sideeffects inall typesof childhoodepilepsies.
Then, in a subgroup of children still on LEV, we prospectively looked
at the correlation between its plasmatic concentration (PC) and
efﬁcacy.
2. Material and methods
2.1. Clinical study
Between July 2006 and June 2007, all patients aged 0–18 years
old identiﬁed in our database who were treated with LEV at CHU
Sainte-Justine’s epilepsy clinic, were included in the study. Their
medical charts were reviewed and the following clinical data
collected: epilepsy syndrome and seizure types, seizure frequency
before and after LEV treatment, AEDs currently and previously
taken, adverse events, and electroencephalographic (EEG) as well
as radiological ﬁndings.
2.2. Pharmacokinetic section
Some patients were still taking LEV when recruited. These
children and their parents were asked to sign an informed consent
form to perform pharmacokinetic studies. A 2–3 ml blood sample
in EDTA tubes was taken from the patients. The time to last LEV
intake was noted for each individual. The plasma samples were
then centrifuged and preserved at 80 8C to be analyzed in our
laboratory using high performance liquid chromatography by
ultraviolet detection (HPLC-UV).
2.3. Instrumentation
This method has already been described by Martens-Lobenhof-
fer and Bode-Bo¨ger.15 Brieﬂy, theHPLC systemconsists of anAgilent
1050 (Agilent Technology company), which includes an automatic
sampler, a degasser, a quaternary pomp, a thermostatted column
compartment and a variable wavelength detector. The chromato-
graphic separation of the analyte is done on a Thermo Hypercarb
(Thermo Electron Company) 150 mm 4.6 mm (5mm particle
size) analytical column protected with a pre-ﬁlter. Data was
collected and analyzed using an Agilent ChemStation software
package, version 9.01. A LEV stock solution was prepared by
dissolving 10 mg of LEV (200 mg provided by UCB: Brussels,
Belgium) in 50 ml water. By spiking drug free human plasma with
working solution, calibration samples between 100 and 0.781mg/
ml were obtained. This calibration range covered the therapeutic
concentration of LEV in our patient samples. A linear regressionwas
done from chromatographic data and allowed us to extrapolate LEV
concentration in each patient sample. Quality control samples were
prepared in three concentrations levels with target values of 0.781,
6.25 and 50mg/ml, a mixture of LEV stock solution and drug free
human plasma.
From a sample (patient, calibration, blank or quality control),
200 ml were mixed with 20 ml of 1.65 M HClO4 (Fisher Scientiﬁc,
ON, Canada), 10 ml of 70% HClO4 (both for maximal protein
precipitation) and 200 ml of cyclohexane (Fisher Scientiﬁc, ON,
Canada) (to extract interferences). The samples were vortexed 10 s
between each addition. When the mixture was completed, the
precipitated proteins were separated by centrifugation at
15 850  g for 30 s. Cyclohexane was aspirated and from the clear
aqueous phase, about 100 ml was transferred into autosampler
vials containingmicroliter inserts (C4010-630P, National Scientiﬁc
Company, TN, USA) and forwarded to the HPLC system.
After injection of 50 ml of the prepared sample into the HPLC
system, the separation of LEV was accomplished by gradientelution. Solvent A consisted of 0.423%H3PO4 (5 mlH3PO4 85% in 1 L
water) (Fisher Scientiﬁc, ON, Canada), and solvent B of acetonitrile
(Fisher Scientiﬁc, ON, Canada). The gradient ratio of solvent B
started at 5%, raised in 5 min to 30% and ﬁnally to 100% for 6 min in
order to elute strongly retained substances on the column. After
each run, a re-equilibration phase of 4 min was necessary to obtain
the starting gradient elution. The ﬂow rate was 1 ml/min and the
column temperature was 35 8C. The wavelength detection was set
to 205 nm. The retention time of LEVwas 4.45  0.10 min under the
described conditions.
2.4. Statistical analysis
Data processing and analysiswere performedwith SPSS Version
14.0 and Graph Pad Prism 4 Version 4.03. All statistical
comparisons used exact Fisher tests, x2 analysis or Student’s t-
tests for independent samples. Mean values were expressed with
their standard error (S.E.M.). Simple linear regressions were done
to correlate LEV plasmatic concentration with dose, time from last
dose, weight, gender and age. A one-way ANOVA was done to
compare the mean LEV plasmatic concentration in each efﬁcacy
group. Curves were compared to evaluate the equivalence of the
slopes. Statistical signiﬁcance was set at p < 0.05.
3. Results
3.1. Study population
As shown in Table 1, our group included 69 patients treated
with add-on LEV, at a mean age of 12  0.5 years (39 males, 30
females). This included 21 patients (30%) with generalized and 48
(70%) with partial epilepsy. At last follow-up, 11 patients were on LEV
monotherapy, 26 were on two AEDs, 21 on 3, 7 on 4, and 4 on 5. Fifty-
seven patients (81.4%) were mentally retarded or developmentally
delayed.
3.2. LEV efﬁcacy
In our cohort, 51 patients (74%) responded to LEV with a
reduction of 50% in seizure frequency (Fig. 1). Sixteen patients
(23%) became seizure free. Only 25% of children did not experience
a 50% decrease in seizure frequency. Patients with generalized
epilepsy had a slightly better outcome than patients with partial
epilepsy (86% and 68%, respectively) but this did not reach
statistical signiﬁcance (p = 0.117).
Other parameters such as: gender, weight, age, age at diagnosis,
seizure type, presence of encephalopathy, presence of co-
morbidity, complications during pregnancy, mental retardation
or developmental delay, family history of epilepsy, number of AEDs
Fig. 1. Impact of LEV on seizure decrease according to epilepsy type. Value  S.E.M.
corresponding to the right y-axis represent the mean daily LEV dose. Four categories of
efﬁcacy (% of seizure decrease) are represented along the x-axis. White bars represent
children with partial epilepsy: 15 patients had a reduction in seizure frequency of less
than 50% and 33 patients hadmore than 50% reduction in seizure frequency—including
12 seizure-free (100%). Grey parts represent those with generalized epilepsy: 3
patients had a reduction in seizure frequency of less than 50% and 18 patients hadmore
than 50%—including 4 seizure-free.
Fig. 3. LEV plasma concentration (PC) in patients suffering from both partial and
generalized epilepsy in each efﬁcacy group (symbols), as a function of the daily
dose. Stars represent patients with a reduction of seizure frequency ranging from25
to 49%, triangles from 50 to 74%, circles from 75 to 99%, and squares represent
seizure free patients. Data not shown for the only patient with a seizure reduction
under 25%.
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had no signiﬁcant impact on LEV efﬁcacy.
3.3. Safety
Most children tolerated LEV well. Fifty-one children (74%)
reported no adverse event. The most frequently observed adverse
events in our population were drowsiness (n = 8), behavioral
trouble (n = 5) characterized by irritability or aggressiveness (all
in children with a prior history of behavioral problems), increase
in seizure frequency (n = 3) and headaches (n = 2). Others
developed tremor, constipation, increase in body weight, or
dizziness (one child in each category) (Fig. 2). Most of these
adverse events occurred within a month of treatment onset. Most
of the patients required only a reduction in dose to limit these side
effects. Overall, only 7 patients had to stop treatment because of
the severity of these adverse events. For those who did not stop,
the adverse events were determined to be tolerable or resolved
over time with continued intake or a dose reduction. An
additional 5 children stopped treatment because of a lack of
efﬁcacy.Fig. 2. LEV-induced adverse events. Total bars: patients who suffered from the
considered side effect (x-axis). Grey parts: patients who stopped the treatment
because of the event severity. Total sample includes 69 epileptic children. Some
patients known more than one adverse event.3.4. Pharmacokinetic data
In order to perform therapeutic drug monitoring, blood
samples were obtained from 37 children. As shown in Table 1, in
this subgroup, the mean age was 11.4  0.8 years, ranging from
2.75 to 18 years old (20 males, 17 females). Sixty percent of patients
in this group suffered from partial epilepsy, and 40% from
generalized epilepsy. Thirty of the 37 patients evaluated (81%)
showed a reduction of seizure frequency of at least 50%, and 11
(30%) were seizure free (Fig. 3). Adverse events occurred in 7 of the
37 patients (19%). The mean LEV plasmatic concentration was
27.44  3.0 mg/ml.
3.5. LEV assimilation and metabolism
We looked at the LEV plasmatic concentration (PC) of the 37
patients, according to dose and time of last intake. The PC
correlated linearly (r2 = 0.65, p < 0.0001) with the dose, decreased
over time in a poorly correlated manner (r2 = 0.25, p = 0.0043), and
reached non-detectable blood levels around 12 h after intake.
Fig. 3 demonstrates (1) that there is no apparent link between
the PC/dose correlation and the epilepsy type (partial: r2 = 0.70;
generalized: r2 = 0.58). The PC range in the partial epilepsy group
(n = 22) was 1.89–74.44 mg/ml and 8.48–72.00 mg/ml in the
generalized epilepsy group (n = 15).
3.6. LEV efﬁcacy related to dose and PC
The majority (60.5%) of the responders received a LEV dose
between 10 and 50 mg/kg/day and had a PC between 5 and 40 mg/
ml (Fig. 3). However within this wide range, there was no
correlation between PC and efﬁcacy (p = 0.6). The PC range of the
11 patients who became seizure free was 6.85–40 mg/ml. While
the PC range of the 6 patients who did not respond was 1.89–
46.66mg/ml (Fig. 3).
4. Discussion
The main ﬁnding of our study is the high efﬁcacy of LEV in a
group of children with refractory epilepsies with limited adverse
event. We also conﬁrmed the lack of correlation between efﬁcacy
and PC, which could be accounted by the speciﬁc mechanism of
action on SV2A.
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4.1.1. Responder rate
Our response rate is in the higher end of the reported ones in
pediatric populations (20–60%).9,16–18 The proportion of seizure-
free patients (23%) is also generally higher than the rates reported
by previous studies in children (average of 16%).10,18–20 This could
be due to the retrospective nature of our study, although we
included all children from our database who received LEV during
the inclusion period. Another possible explanation could be our
frequent use of LEV in generalized epilepsies. Although the
response rate did not differ signiﬁcantly between patients with
partial or generalized epilepsies, it was higher in the generalized
epilepsy group (68% versus 86%, respectively). Children with
generalized epilepsy have shown a better response to LEV than
children with partial epilepsy in a number of studies.13,18,21
However, some studies reported that LEVwasmore effective in the
treatment of partial rather than generalized epilepsies, supporting
its large spectrum of efﬁcacy.7,8
Our high responder rate could also be due to a relatively short
follow-up period. However, no data is available to support the
development of LEV tolerance in humans, although such an effect
has been described in kindled rats.22
4.2. LEV predictors of efﬁcacy
Only about a quarter of the patients were considered to be non-
responders and 17% discontinued treatment. We therefore could
not identify predictors of efﬁcacy in a limited cohort of patients
(n = 69). The number of patients who failed or stopped treatment
due to adverse events or a lack of LEV efﬁcacy is very variable in the
literature (9–73% and 6–27%, respectively).18,19,23 Our study
showed that LEV is highly effective in children with generalized
epileptic syndromes. Efﬁcacy has also been reported in children
with catrastophic epilepsies such as Lennox–Gastaut syndrome
and cryptogenic infantile spasms.24,25
We studied the inﬂuence of clinical parameters on LEV efﬁcacy
such as: age, gender, or previous AEDs. In our cohort, no variable
was positively correlated with LEV efﬁcacy. Von Stuelpnagel et al.
reported that age correlatedwith LEV response, with patients older
than 18 years old responding better than younger patients. This
effect of age was not observed within our pediatric population.18
Although the vast majority of our refractory patients were
developmentally delayed (81%), this did not have a negative
impact on the efﬁcacy rate compared to other studies. Moreover,
statistical analysis did not reveal any signiﬁcant relationship
between developmental delay and LEV efﬁcacy (p = 0.175). This
high efﬁcacy of LEV in amentally handicapped population had also
been reported previously.26
4.3. Safety
Our study revealed that LEV is an AEDwith a high tolerability in
children, both for partial and generalized epilepsy. Adverse events
were observed in 19 patients (27%). The previously reported rates
vary from 9.5 to 40%.14,16–18,19,23 In our population, side effects
caused by LEV were mild to moderate, and often reversible (63%)
(Fig. 2). Drowsiness was the most commonly reported adverse
event and was typically transient. We did not observe gastro-
intestinal disorders as other studies reported.14,20,27,28 The number
of patients who stopped treatment due to those side effects was
similar to previous studies.10,20
As opposed to recent works,13,29 we found a very low number of
patients who experienced an increase in seizure frequency
following treatment onset (n = 3; 4%). Out of these patients, two
had to cease treatment and a dose adjustment allowed the third tocontinue with LEV therapy. This LEV-induced increase in seizure
frequency was observed only in children suffering from partial
epilepsy. Whether this represents a natural ﬂuctuation in their
seizure pattern or a change due to LEV’s mechanism of action is
unknown.
4.4. Therapeutic monitoring of LEV
This is the ﬁrst study to report on therapeutic monitoring of LEV
in a pediatric population. Previous studies in adults did not always
evaluate the correlation between the LEV PC with the clinical
response.30–32 Our data demonstrates that there is no linear
correlation between LEV PC and efﬁcacy. However, we found that
60%of the respondershada LEVPCsituatedbetween5and40mg/ml
with no child responding at lower levels, with a daily dose ranging
from 10 to 50mg/kg. These numbers might be used in subsequent
studies as a potential therapeutic range for children. The mean LEV
PC in our patients is higher than those reported in adults.33 Other
studies also showed a LEV PC range with maximum concentrations
that were lower than in ours (e.g. 33.5, 48.2mg/ml in comparison to
74.44).31,33 This may be caused by differences in metabolic rates in
patients of different age or ethnic background of each population,
and to a better tolerability in children. We found no signiﬁcant
correlation between LEV PC and age, gender and epilepsy type in
children. These observations suggest these parameters do not affect
LEV assimilation, even if there is variability between patients.
5. Conclusion
Our results suggest that LEV is a broad spectrum anticonvulsant
in children and can be usedwith great success also in patients with
generalized epileptic syndromes. Its great safety proﬁle, its lack of
drug interaction and its efﬁcacy in special populations are novel
arguments for its utilization in children with benign as well as
refractory epilepsies.
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